| Faculty (Department Wise)+ |
|---|
| ----------------------------- |
| Chemical Sciences > |
| Pharmaceutical Analysis > |
| Biological Sciences > |
| Pharmaceutics > |
| Pharmaceutical Management > |
| Medical Devics > |
| Natural Products > |
| Regulatory Affairs > |
| Pharmacoinformatics > |
| ----------------------------- |
| Young Scientists > |
| Guest Faculty > |
| ----------------------------- |
| Staff + |
| ----------------------------- |
| Technical Staff > |
| Administrative Staff > |
Prof. Nagula Shankaraiah is an accomplished medicinal and synthetic organic chemist with a distinguished record in academics and research. Over the course of his career, he has led numerous research programs focused on the rational design and synthesis of novel chemical entities (NCEs), inspired from both natural and privileged scaffolds as anti-cancer agents. He has made notable contributions for the development of cytotoxic agents targeting critical cancer pathways, including epigenetic regulators and multi-kinase inhibition, tubulin, and topoisomerase II, dual target inhibition such as VEGFR-2, CDKs, HDACs. His research encompasses aspects of modern drug discovery, including structure–activity relationship (SAR) elucidation, hit identification, hit-to-lead progression, and lead optimization. In addition to his expertise in medicinal chemistry, he is also highly proficient in the development of synthetic methodologies. His work integrates sustainable and green chemistry principles, employing state-of-the-art techniques such as click chemistry, one-pot domino transformations, and C–H activation/functionalization. He has also contributed to mechanistic organic chemistry by live ESI/MS and NMR studies. His scientific contributions are reflected in an extensive portfolio of high-impact publications and patents, underscoring his enduring impact in the field of medicinal and organic chemistry.
Full Profile
Accomplished Medicinal, Synthetic and Natural Product Organic Chemist with 30 years of industrial and academic research experience. Associated with the Indian Pharma, CRO and reputed academic institutions viz., Dr Reddy's Laboratories, Aurigene Discovery Technologies Ltd., Biocon BMS Research Centre, Albany Molecular Research, Sri Sathya Sai Institute of Higher Learning and National Institute of Pharmaceutical Education & Research, Hyderabad in various positions and roles of scientific and managerial responsibilities. Led several integrated drug discovery programs encompassing all stages of drug discovery viz., Hit generation, Hit to Lead and Lead optimization involving both Natural Product and Synthetic products in the areas of oncology, metabolic disorders, and infectious diseases. The programs carried out include both internal programs and collaborative research programs with several pharmaceutical companies/Institutes. While some of the programs have successfully transitioned to the late Lead Optimization stages (pre-clinical/clinical), one of the programs has led to a Phase 2 clinical candidate. Experienced in leading cross-functional teams which include Medicinal Chemistry, biochemistry, pharmacology, DMPK and toxicology. Several patents/publications have been filed/published.
Full Profile
Dr. Venkata Madhavi Yaddanapudi brings over eighteen years of post-PhD experience. With 5 plus years of industrial experience in API process R&D at Dr. Reddy’s Laboratories, IPDO, she joined NIPER, Hyderabad in the Process Chemistry department which is a part of Chemical Sciences now. She did her doctoral studies at Indian Institute of Chemical Technology(IICT), Tarnaka, Hyderabad. She also has Six Sigma green belt certification, a post graduate diploma in statistical quality control from Indian Statistical Institute and a PG Diploma in Patents Law She teaches courses like Logic in organic synthesis, Industrial Process and Scale up techniques, Stereochemistry and Drug action, Synthetic Aspects of Process Chemistry, Synthetic Bulk drug technologies and takes general laboratory sessions. Seven students have been awarded PhD in her guidance and five are pursuing at present. She has also guided more than forty MS students in their dissertation works. Many of them are pursuing higher studies and others are in good positions in various pharmaceutical industries. Her research interests include, “Structure based drug design and synthesis of new anti-microbial agents”, with particular focus on tackling the AMR problem in Mycobacterium tuberculosis. Her research group has two granted patents in the development of NCE’s for Tuberculosis and more than 95 publications in international peer reviewed journals. Her group is also involved in development of cost effective synthetic routes for API’s and API intermediates and novel sustainable and green methodologies.
Full Profile
Dr. Priyanka Bajaj’s group has particular interest in green chemistry to make our pharmaceutical and fine chemical industry and industrial products more environmentally friendly and affordable for everyone. Her research mainly focuses on developing green biocatalytic processes and enzymes for complex synthetic chemistry challenges mainly focusing on synthesis of chiral compounds of pharmaceutical importance. The enzymes are studied in detail for their structure activity relationship and engineered using the techniques of directed evolution. The libraries of various substrates and enzymes are further screened in high throughput mode using LC/MS, GC/MS and UV-Vis spectrophotometry and upscale and downscale processes are optimized. The group is working on exploring wide range of enzymes including Aldehyde dehydrogenases (ALDHs), Myoglobin, P450s and others.
Her Research Interest includes the below
Dr. Kaki Venkata Rao’s research team primarily focuses on the discovery of novel anti-inflammatory and anti-proliferative agents through both synthetic and computational approaches. Novel selenated heterocycles, such as selenazolines and quinolines, are currently being investigated as potential kinase and MMP-9 inhibitors. The team has also developed new synthetic methodologies to produce these bioactive compounds. Additionally, efforts are underway to scale up the production of active pharmaceutical ingredients (APIs), including Melitracin and other compounds synthesized via Grignard reactions. Furthermore, the team is exploring the development of anti-inflammatory formulations based on natural product extracts from medicinal plants.
Full Profile
Dr. Sai Sudhir’s group envisions to develop cost effective and new approaches to API’s and KSM’s. Our research group plans to develop chiral auxiliary based unified approach to diverse KSM’s of medicinal chemistry interest. We also plan to generate novel approaches to diverse heterocyclic libraries of compounds and study their bioactivity. Non-metallic approaches to reductive strategies are being explored. Our research would also focus on developing alternate strategies to deprotection of protecting groups and to synthesize unnatural amino acids of medicinal importance.
Full Profile